Literature DB >> 18838583

Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Klaudia Kosowska-Shick1, Lois M Ednie, Pamela McGhee, Kathy Smith, Cynthia D Todd, Amanda Wehler, Peter C Appelbaum.   

Abstract

All 982 methicillin-resistant Staphylococcus aureus strains collected from August 2006 to December 2007 were tested for vancomycin susceptibility by using 3-microg/ml vancomycin brain heart infusion screening plates, a vancomycin Etest, and a vancomycin/teicoplanin macro Etest. Three vancomycin-intermediate Staphylococcus aureus (VISA) (0.3%) and two heterogeneous VISA (0.2%) isolates were identified. The screening method yielded 895 cases of < or =1 colony and 87 positive results (with growth of >1 colony after 48 h); further Etests showed 82/87 isolates with growth on screening plates to be false positive. Repeat testing showed a false-positivity rate of only 15 of the original 87 isolates by plate screening.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18838583      PMCID： PMC2592881          DOI： 10.1128/AAC.01073-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

3.  New method for typing Staphylococcus aureus strains: multiple-locus variable-number tandem repeat analysis of polymorphism and genetic relationships of clinical isolates.

Authors:  Artur Sabat; Jolanta Krzyszton-Russjan; Wojciech Strzalka; Renata Filipek; Klaudia Kosowska; Waleria Hryniewicz; James Travis; Jan Potempa
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 4.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

5.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Authors:  Anne Yusof; Anette Engelhardt; Asa Karlsson; Lina Bylund; Pamela Vidh; Karen Mills; Mandy Wootton; Timothy R Walsh
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

Review 7.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2007-09-20       Impact factor: 5.283

8.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Authors:  Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

9.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

Authors:  Dawn M Sievert; James T Rudrik; Jean B Patel; L Clifford McDonald; Melinda J Wilkins; Jeffrey C Hageman
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

10.  Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.

Authors:  Yasmin Maor; Galia Rahav; Natasha Belausov; Debby Ben-David; Gill Smollan; Nathan Keller
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948
View more
  23 in total

Review 1.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.

Authors:  Riad Khatib; Kathleen Riederer; Mamta Sharma; Stephen Shemes; Sugantha P Iyer; Susan Szpunar
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

3.  Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.

Authors:  K Riederer; S Shemes; P Chase; A Musta; A Mar; R Khatib
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

4.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

5.  Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.

Authors:  Santiago M Lattar; Mariángeles Noto Llana; Philippe Denoël; Sophie Germain; Fernanda R Buzzola; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

6.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

7.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

8.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

9.  Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus.

Authors:  Carey-Ann D Burnham; Carol J Weber; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

10.  Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.

Authors:  Heather J Adam; Lisa Louie; Christine Watt; Denise Gravel; Elizabeth Bryce; Mark Loeb; Anne Matlow; Allison McGeer; Michael R Mulvey; Andrew E Simor
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.